Eevia Health Plc

Eevia Health Abp has issued a notice to its shareholders for an Extraordinary General Meeting scheduled for 5 June 2024, at the company's main office in Finland. The agenda includes the election of persons to scrutinize minutes and supervise vote counting, recording the legality and attendance of the meeting, and authorizing the Board of Directors to decide on the issuance of shares, options, and other special rights. The Board proposes the issuance of up to 70,000,000 shares, with terms to be decided by the Board. The authorization would be valid until 30 June 2025. The notice also provides detailed instructions for shareholders' participation, registration, and representation. Shareholders are invited to register by 31 May 2024. All related documents are available on the company's website.

Eevia Health Plc's Board of Directors is preparing for a rights issue with preferential rights for existing shareholders. The rights issue is subject to approval by an Extra General Meeting (EGM) scheduled for June 5, 2024. The target amount is approximately SEK 28.6 million, which will primarily finance working capital, loan repayment, recruitment, investments, projects, corporate and marketing activities. The rights issue is covered by 50% subscription and guarantee commitments. The subscription period for the rights issue will run from June 14, 2024, to June 28, 2024. Finnish shareholders must transfer their shares to Euroclear Sweden's book-entry system before the record date to trade on subscription rights and BTAs on Spotlight Stock Market Sweden.

Eevia Health Plc is showcasing its products at the Vitafoods 2024 nutraceutical tradeshow in Geneva, Switzerland. The company has received positive feedback on its Fenoprolic® product, which has a bioactivity profile similar to the leading pine bark extract in the market. This has led to potential discussions about using Fenoprolic® as an active ingredient in supplements and expected orders after the tradeshow. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily harvested from Finnish and Swedish forests. The extracts are sold globally as ingredients in dietary supplements and food brands. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc has announced changes to its financial calendar due to practical reasons and public holidays in May. The release of its Interim Report for Q1-2024 has been moved from May 20 to May 22, 2024. The company will publish its statutory financial statements and auditor's report on June 7, 2024. The Annual General Meeting of the Shareholders will be held on June 28, 2024, with the notice being published on June 7, 2024. Eevia Health, founded in 2017, is a manufacturer of organically certified plant extracts, primarily harvested from the Finnish and Swedish forests. The company listed its shares on the Spotlight Stock Market in Sweden in June 2021.

Eevia Health Plc, a Finnish company that produces bioactive compounds from plant materials, has received a sales order of approximately 51 kEUR from a European nutraceutical brand owner based in Sweden. The order, set for delivery in June 2024, is for Eevia's Feno-Myrtillus® 1, a Bilberry extract standardized for anthocyanins. The customer, which sells herbal dietary supplements and cosmetics in over 36 countries, has been a repeat client of Eevia, buying directly from the company without using a distributor. Eevia Health, founded in 2017, operates a green-chemistry production facility in Finland and is known for its high-quality, organically certified plant extracts.

Eevia Health has received multiple orders for its pine bark, bilberry, and lingonberry extracts, totaling KSEK 1 045 (KEUR 90) from various European and Australian customers. The orders include Fenoprolic 70 Organic (Pine bark extract), Feno-Myrtillus 25 Organic (Bilberry Extract), and Lingonberry Extract with Acacia. These orders are from several European customers with consumer brands in foods, drinks, and supplements, as well as an order for a pet food company and an Australian company. The company expects further repeat orders from the same customers in the future. Eevia Health is a manufacturer of 100% organically certified plant extracts, primarily wild harvested from Finnish and Swedish forests.

Eevia Health has received multiple sales orders from various European customers, totaling approximately 518 kSEK or 50 kEUR. The orders are for a range of products including Chaga extract, bilberry extracts, and Pine bark extract, and came from Finnish and European customers in the whole foods, drinks, and supplement sectors. The company, which has the products in stock, anticipates more repeat orders from the same customers. Eevia Health, established in 2017, is a manufacturer of 100% organically certified plant extracts, primarily harvested from Finnish and Swedish forests. The company listed its shares on the Spotlight Stock Market in Sweden in 2021.

Eevia Health has completed a project documenting the bioactivity of its products, co-funded by Business Finland. The project, which was conducted in 2023 and reported in February 2024, involved extensive in vitro testing of Eevia's top extracts. The study yielded promising results, particularly for one ingredient. The company is now planning a follow-up project, "Global Vision", for this ingredient and is seeking approximately €800k in non-dilutive funding. The project aims to bring the product to market for human use. Eevia Health, which manufactures organically certified plant extracts, primarily sources its materials from the forests of Finland and Sweden.

Eevia Health has received a blanket sales order worth 1,472 kSEK / 142 kUSD for its elderberry extract product, Feno-Sambucus™ 7 Organic, from US distributor Select Ingredients. The order will be fulfilled over several months and is a repeat order from an end customer in the whole foods and drinks sector, which is experiencing rapid growth. Eevia Health expects further repeat orders in the future. The company, which was founded in 2017, extracts bioactive compounds from plant materials, primarily harvested from Finnish and Swedish forests. It operates a green-chemistry production facility in Finland and listed its shares on the Spotlight Stock Market in Sweden in June 2021.

Eevia Health Plc has updated its Information Policy and increased the threshold for sales orders and contracts that warrant a press release from 10 KEUR to 50 KEUR. The change is in response to criticism from investors who felt the company was providing too much information about smaller orders. The company will also issue a press release when several smaller orders accumulate to a value over 50 KEUR. Eevia Health Plc, a manufacturer of organically certified plant extracts, was founded in 2017 and listed its shares on the Spotlight Stock Market in Sweden in 2021.